コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 oites and, therefore, preventing relapses of vivax malaria.
2 primaquine effectively prevents relapses of vivax malaria.
3 rophylaxis agents do not prevent relapses of vivax malaria.
4 age parasites isolated from patients with P. vivax malaria.
5 exploited to develop therapeutics against P. vivax malaria.
6 development of blood stage vaccines against vivax malaria.
7 vaccines and effective treatments to combat vivax malaria.
8 n Southeast Asia, provides a barrier against vivax malaria.
9 een has been reported in cases of Plasmodium vivax malaria.
10 8; p=0.0473) following recurrent symptomatic vivax malaria.
11 the most promising vaccine candidate for P. vivax malaria.
12 he next generation of potent vaccines for P. vivax malaria.
13 alaria, but have not been assessed in severe vivax malaria.
14 asitaemia rapidly in both P falciparum and P vivax malaria.
15 nts with Plasmodium falciparum or Plasmodium vivax malaria.
16 define the role of these molecules during P. vivax malaria.
17 croscopy (the gold standard) for detecting P vivax malaria.
18 exploited to develop therapeutics against P. vivax malaria.
19 igated antimalarial treatment efficacy in P. vivax malaria.
20 ng-inhibitory antibodies through exposure to vivax malaria.
21 stage parasite clearance of uncomplicated P. vivax malaria.
22 t factors in the provocation of a relapse of vivax malaria.
23 cule an attractive vaccine candidate against vivax malaria.
24 pment of a broadly effective vaccine against vivax malaria.
25 ot be the only cause of recurrent Plasmodium vivax malaria.
26 he only drug available to prevent relapse in vivax malaria.
27 pregnancy-associated malaria, and Plasmodium vivax malaria.
28 he treatment of Plasmodium falciparum and P. vivax malaria.
29 , would confer a selective advantage against vivax malaria.
30 cond-generation vaccine candidate against P. vivax malaria.
31 ccine for antibody-mediated immunity against vivax malaria.
32 tial cohorts of adults with uncomplicated P. vivax malaria (10 patients) or P. falciparum malaria (11
33 evere vivax malaria as compared to nonsevere vivax malaria (2.5 vs 1 g/dL; P = .0001), markers of int
34 ctive was to study whether people exposed to vivax malaria acquire antibodies that have the ability t
35 range, 0.85 to 1.14) in the patients with P. vivax malaria and 0.90 hours (range, 0.68 to 1.64; inter
36 ile range, 8 to 16 hours in patients with P. vivax malaria and 10 to 16 hours in those with P. falcip
37 the radical curative treatment of Plasmodium vivax malaria and can cause haemolysis in G6PD deficient
39 e a better understanding of the pathology of vivax malaria and development of antimalarial drugs and
40 temporal epidemiological cases of Plasmodium vivax malaria and land-use irrigation from remote sensin
44 bility) were reduced in patients with severe vivax malaria and those with nonsevere vivax malaria, co
45 h severe vivax malaria, those with nonsevere vivax malaria, and healthy controls, respectively; P = .
48 ficant illness in travelers, but relapses of vivax malaria are not prevented with the current first-l
49 lopment of vaccines and drugs for Plasmodium vivax malaria are the inability to culture this species
50 ll in hemoglobin level was greater in severe vivax malaria as compared to nonsevere vivax malaria (2.
51 plasma from populations naturally exposed to vivax malaria, as well as antisera obtained by vaccinati
52 in plasmas from people naturally exposed to vivax malaria, as well as in antisera obtained by animal
55 CQ were effective and well-tolerated for P. vivax malaria, but high rates of recurrent parasitemia w
59 evere vivax malaria and those with nonsevere vivax malaria, compared with healthy controls (median L-
60 mic downturn, difficulties in elimination of vivax malaria, development of pyrethroid resistance in s
63 of inhibitory receptors on T cells during P. vivax malaria impairs parasite-specific T-cell effector
64 How much they contribute to the burden of P. vivax malaria in children living in highly endemic areas
66 e is the first-line treatment for Plasmodium vivax malaria in most endemic countries, but resistance
68 the risk of re-presentation to hospital with vivax malaria in patients prescribed dihydroartemisinin-
73 decrease in the prospective risk of clinical vivax malaria in subjects with the strongest BIAb respon
77 Effective control strategies targeting P. vivax malaria is hindered by our limited understanding o
81 function is impaired in nonsevere and severe vivax malaria, is associated with reduced L-arginine bio
82 vax malaria (n = 9), patients with nonsevere vivax malaria (n = 58), and healthy controls (n = 79), w
84 nistration of primaquine for treatment of P. vivax malaria needs to be urgently considered to prevent
85 13, there were 86,797 documented episodes of vivax malaria, of which 62,492 (72.0%) were included in
86 P. vivax on BS; 2 received a diagnosis of P. vivax malaria on the basis of RDT but BSs were negative;
87 een associated with protection from clinical vivax malaria or reduced Plasmodium vivax density, inclu
91 t increased risk of death from falciparum or vivax malaria, particularly in those with concurrent sev
92 nses against all PvTRAgs in the sera from 96 vivax malaria patients and 40 healthy individuals using
93 the serum proteome alterations in non-severe vivax malaria patients before and during patient recuper
95 lated with our observations in a panel of 50 vivax malaria patients where schizonts were completely a
96 t comprehensive serum proteomics analysis of vivax malaria patients with different levels of parasite
97 is to compare the serum proteome profiles of vivax malaria patients with low (LPVM) and moderately-hi
98 compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH flu
102 with acute, uncomplicated P falciparum or P vivax malaria received artefenomel in a single oral dose
103 es of chloroquine resistance according to P. vivax malaria recurrence rates by day 28 whole-blood chl
104 Some data lend support to the notion that vivax malaria relapse followed febrile illness caused by
105 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious th
107 terventions that will reduce transmission of vivax malaria requires knowledge of Plasmodium vivax gam
108 laria convened the first malaria conference, Vivax Malaria Research: 2002 and Beyond, devoted entirel
109 e FY*O allele confers complete resistance to vivax malaria, suggesting that this allele has been the
110 1.49, 1.73, and 1.97 in patients with severe vivax malaria, those with nonsevere vivax malaria, and h
112 esunate-mefloquine (AS-MQ) for uncomplicated vivax malaria was conducted in 3 district hospitals in S
113 hlorproguanil-dapsone for the treatment of P vivax malaria was conducted in eastern Afghanistan and n
117 tan and 452 in Afghanistan) with confirmed P vivax malaria were enrolled and followed up daily for 4
119 equally effective in both P falciparum and P vivax malaria, with median parasite clearance half-lives
121 A successful vaccine against Plasmodium vivax malaria would significantly improve the health and
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。